D-Index & Metrics Best Publications

Home
Alexander Drilon

Alexander Drilon

Memorial Sloan Kettering Cancer Center
United States

Research.com Recognitions

Awards & Achievements

2022 - Research.com Rising Star of Science Award

Overview

What is he best known for?

The fields of study he is best known for:

Cancer
Gene
Internal medicine

Alexander Drilon mainly investigates Cancer research, Entrectinib, Adenocarcinoma, Internal medicine and Oncology. His Cancer research research includes themes of Mutation, Gene, Mutant, Tyrosine kinase and Pathology. His Entrectinib study is within the categories of Trk receptor and Cancer.

His Adenocarcinoma research includes elements of Cabozantinib, Bioinformatics, KRAS, Lung and Lung cancer. His study on Clinical trial is often connected to Response Evaluation Criteria in Solid Tumors as part of broader study in Internal medicine. His Clinical trial study integrates concerns from other disciplines, such as Young adult and Odds ratio.

His most cited work include:

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (852 citations)
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas (378 citations)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping (367 citations)

What are the main themes of his work throughout his whole career to date?

Alexander Drilon mainly focuses on Cancer research, Internal medicine, Oncology, Lung cancer and Cancer. His Cancer research research is multidisciplinary, relying on both ROS1, Trk receptor, Kinase and Targeted therapy. In Oncology, Alexander Drilon works on issues like Chemotherapy, which are connected to Immunotherapy.

His Lung cancer study incorporates themes from KRAS, Cabozantinib and Adenocarcinoma. The study incorporates disciplines such as Carcinoma and Pathology in addition to Adenocarcinoma. His Cancer research is multidisciplinary, incorporating elements of Fusion gene, Drug resistance, MAPK/ERK pathway and Confidence interval.

He most often published in these fields:

Cancer research (60.81%)
Internal medicine (54.39%)
Oncology (46.28%)

What were the highlights of his more recent work (between 2019-2021)?

Cancer research (60.81%)
Internal medicine (54.39%)
Oncology (46.28%)

In recent papers he was focusing on the following fields of study:

Cancer research, Internal medicine, Oncology, Lung cancer and Trk receptor are his primary areas of study. His Cancer research research includes elements of Tyrosine kinase, ROS1 and Receptor tyrosine kinase, Kinase. His Tyrosine kinase study integrates concerns from other disciplines, such as Mutation and Cabozantinib.

Alexander Drilon is studying Entrectinib, which is a component of Oncology. Alexander Drilon has included themes like Targeted therapy and Adenocarcinoma in his Lung cancer study. His research integrates issues of Tropomyosin receptor kinase A, Gene and Immunotherapy in his study of Trk receptor.

Between 2019 and 2021, his most popular works were:

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials (196 citations)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials (196 citations)
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls (111 citations)

In his most recent research, the most cited papers focused on:

Cancer
Gene
Internal medicine

His primary areas of investigation include Cancer research, Internal medicine, Lung cancer, Cancer and Clinical trial. His Cancer research study combines topics in areas such as Tyrosine kinase, ROS1, Trk receptor and Gene. In his research on the topic of Internal medicine, Central nervous system is strongly related with Oncology.

The concepts of his Cancer study are interwoven with issues in Druggability and Signal transduction. His work deals with themes such as Adverse effect and Progression-free survival, which intersect with Clinical trial. The study incorporates disciplines such as Young adult and Entrectinib in addition to Adverse effect.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois.
The New England Journal of Medicine (2018)

1751 Citations

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena.
Lancet Oncology (2020)

703 Citations

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel.
Cancer Discovery (2017)

604 Citations

NTRK fusion-positive cancers and TRK inhibitor therapy

Emiliano Cocco;Maurizio Scaltriti;Alexander Drilon.
Nature Reviews Clinical Oncology (2018)

576 Citations

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres;A. Drilon;A. Lusque;L. Mhanna.
Annals of Oncology (2019)

563 Citations

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara.
Cancer Discovery (2013)

513 Citations

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon.
Nature (2018)

496 Citations

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

Paul K. Paik;Paul K. Paik;Alexander Drilon;Alexander Drilon;Pang Dian Fan;Helena Yu;Helena Yu.
Cancer Discovery (2015)

464 Citations

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron.
Cancer Discovery (2017)

413 Citations

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago.
Lancet Oncology (2020)

405 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Alexander Drilon